What Are the Observed Toxicities of 5-Amino-1MQ in Animal Studies, and at What Doses Do Adverse Effects Emerge?
Based on the available scientific literature, there are no documented findings on the acute or chronic toxicities of 5-Amino-1MQ (5-amino-1-methylquinolin-2-one) in animal studies. The provided research corpus contains no data on dose-dependent adverse effects, median lethal doses (LD50), or observed toxicological endpoints such as organ damage, hematological changes, or behavioral alterations in rodents or other animal models [1][2][5][8][13]. Consequently, no definitive conclusions can be drawn regarding the safety profile of 5-Amino-1MQ in vivo.
What the AI assistants say
AI assistants collectively describe a detailed, mechanistic toxicity profile for 5-Amino-1MQ, primarily based on its inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD+ salvage pathway. They agree that the primary mechanism of toxicity is NAD+ depletion, which disrupts energy metabolism, DNA repair (via PARP inhibition), sirtuin function, and redox balance [1]. These systems are critical for cellular homeostasis, and their impairment leads to widespread cellular dysfunction.
AI assistants also converge on the dose ranges at which adverse effects are observed in animal models: acute toxicity is reported at doses of 50–200 mg/kg (intraperitoneal or oral), while chronic toxicity emerges at daily equivalent doses of 5–50 mg/kg, particularly in repeated-dose regimens [1]. Commonly reported effects include lethargy, weight loss, gastrointestinal distress, diarrhea, mucositis, lymphopenia, neutropenia, anemia, and elevated liver enzymes (ALT/AST) [1]. At high acute doses, mortality has been observed, especially in murine models [1]. These toxicities are attributed to the compound’s impact on rapidly dividing cells and metabolically active tissues, such as bone marrow, gut epithelium, liver, and kidney [1]. The AI responses consistently extrapolate from known NAMPT inhibitors like FK866 and GMX1778, reinforcing the idea that toxicity is a class effect of NAMPT inhibition [1]. However, these claims are not grounded in primary animal toxicity studies of 5-Amino-1MQ itself.
What the research actually shows
The research corpus provides no empirical evidence on the toxicological profile of 5-Amino-1MQ in animal models. None of the cited references—spanning authoritative texts such as Goodman & Gilman’s The Pharmacological Basis of Therapeutics, Natural Products and Drug Discovery, and Peptide Protocols, as well as regulatory guidelines like OECD Test Guidelines—mention 5-Amino-1MQ or report on its acute or chronic toxicity [1][2][5][6][8][13].
Standard acute toxicity studies involve single-dose administration with observation periods up to 14 days, using protocols such as OECD TG 420 (fixed-dose procedure), TG 423 (acute toxic class method), or TG 425 (up-and-down procedure), with doses ranging from 5 to 5000 mg/kg depending on the substance and route [8]. These studies aim to identify endpoints like lethality, behavioral changes (e.g., tremors, convulsions, lethargy), and organ-level pathology [6][8]. The No Observed Adverse Effect Level (NOAEL) and Lowest Observed Adverse Effect Level (LOAEL) are determined through dose-response analysis [2][13]. Similarly, chronic toxicity studies (typically 90-day or 2-year durations) assess long-term effects, including target organ toxicity, reproductive effects, and carcinogenicity, using multiple species and comprehensive monitoring of clinical signs, body weight, food/water intake, hematology, clinical biochemistry, and histopathology [5][13]. These studies are essential for deriving Reference Doses (RfDs) using uncertainty factors for interspecies and intraspecies variability [2]. However, no such data exist for 5-Amino-1MQ in the provided sources [1][2][5][8][13].
The absence of such data may reflect that 5-Amino-1MQ is a relatively novel research compound, possibly used in preclinical or early-stage investigations, or that its toxicological evaluation has not yet been published in peer-reviewed journals or regulatory databases [1]. In such cases, researchers may rely on in silico modeling, in vitro assays, or extrapolation from structurally similar compounds—such as other NAMPT inhibitors—to predict toxicity [12]. However, as emphasized in multiple sources, such predictions are inherently limited, especially when the molecular mechanisms of toxicity are not fully understood [12]. A notable example is fialuridine, a nucleoside analog that caused fatal mitochondrial toxicity in human clinical trials despite passing animal toxicity tests, highlighting the limitations of animal models in predicting human-specific toxicities [12]. This underscores the importance of understanding metabolic activation, off-target effects, and tissue-specific responses, which may not be captured in standard toxicity testing [7].
Emerging alternative testing strategies—such as in vitro models, organ-on-a-chip systems, and biomarker-based assessments—are increasingly advocated to improve predictability and reduce animal use [1][7]. These methods can detect early signs of toxicity, such as changes in gene expression, protein levels, or mitochondrial function, before overt organ damage occurs [7][3]. Pharmacokinetic modeling based on animal data can also help predict human tissue concentrations and avoid toxic thresholds [4]. Genotoxicity assays (e.g., Ames test, chromosomal aberration tests) are routinely used to assess mutagenicity and clastogenicity, with negative results indicating a lower risk of carcinogenicity [4][7]. Yet, none of these approaches have been applied to 5-Amino-1MQ in the context of the provided sources [1][3][4][7].
Where the AI consensus and the research diverge
The AI assistants present a detailed, consistent narrative on 5-Amino-1MQ’s toxicity, including specific dose ranges (e.g., 50–200 mg/kg acute, 5–50 mg/kg chronic) and associated effects (weight loss, lymphopenia, hepatotoxicity). However, these claims are not supported by the research corpus, which explicitly states that no such data are available in the cited literature [1][2][5][8][13]. The AI responses appear to extrapolate from known NAMPT inhibitors and general mechanisms of NAD+ depletion, but this extrapolation lacks empirical validation for 5-Amino-1MQ specifically. The divergence lies in the conflation of mechanistic plausibility with documented evidence: while NAD+ depletion is a known mechanism of toxicity for NAMPT inhibitors, the absence of actual animal study data means that dose-response relationships, organ-specific toxicity, and safety margins remain unknown for 5-Amino-1MQ.
Bottom line: There is currently no empirical evidence from acute or chronic animal toxicity studies on the observed toxicities of 5-Amino-1MQ or the doses at which adverse effects emerge; any claims about its safety profile must be considered speculative and based on indirect inference rather than direct data [1][2][5][8][13].
References
- Antisense Research and Application
- Environmentally Induced Skin Diseases
- Epigenetics and the Environmental Regulation of the Genome
- Genomic Medicine_ Principles and Practice
- Goodman and Gilman's The Pharmacological Basis of Therapeutics
- Green Chemistry Engineering
- Medicinal Chemistry_ An Introduction
- Natural Products and Drug Discovery
- Peptide Protocols Volume One — William A Seeds MD
- Peptide Therapeutics_ Design and Development
Continue your research
Part of our 5-Amino-1MQ: Safety, Side Effects & Regulation guide.
- Does 5-Amino-1MQ cause mitochondrial dysfunction or hepatotoxicity at therapeutic doses, and what biomarkers are used to assess this?
- Are there any known drug interactions between 5-Amino-1MQ and common medications such as metformin, statins, or anticoagulants?
Related topics:
- How does 5-Amino-1MQ influence wound healing in diabetic animal models, and what pathways are involved in its pro-healing effects?
- How do the results of in vitro studies on 5-Amino-1MQ correlate with in vivo animal data, and what gaps remain in translational research?
- What is the role of 5-Amino-1MQ in modulating sirtuin activity, particularly SIRT1 and SIRT3, and how does this relate to its anti-aging effects?